Koers Vivoryon Therapeutics AG Euronext Amsterdam
Aandelen
DE0007921835
Biotechnologie & Medisch Onderzoek
Omzet 2023 | -3,62 mln. -3,9 mln. | Omzet 2024 * | - | Marktkapitalisatie | 20,72 mln. 22,32 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2023 | -28 mln. -30,15 mln. | Nettowinst (verlies) 2024 * | -18 mln. -19,38 mln. | EV/omzet 2023 | -53,5 x |
Nettoliquiditeiten 2023 | 18,52 mln. 19,95 mln. | Nettoliquiditeiten 2024 * | 19,55 mln. 21,05 mln. | EV/omzet 2024 * | - |
K/w-verhouding 2023 |
-7,27
x | K/w-verhouding 2024 * |
-1,11
x | Werknemers | - |
Dividendrendement 2023 * |
-
| Dividendrendement 2024 * |
-
| Vrij verhandelbaar | 66,56% |
Recentste transcriptie over Vivoryon Therapeutics AG
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Frank Weber
CEO | Chief Executive Officer | 64 | 01-01-12 |
Anne Doering
DFI | Director of Finance/CFO | - | - |
Director/Board Member | 56 | 31-08-18 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 74 | 01-01-07 | |
Director/Board Member | 54 | 01-01-07 | |
Anne Doering
DFI | Director of Finance/CFO | - | - |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+17,96% | 44,96 mld. | |
+1,17% | 42,65 mld. | |
+48,77% | 41,85 mld. | |
-4,27% | 29,04 mld. | |
+11,42% | 26,08 mld. | |
-21,39% | 19,03 mld. | |
+4,86% | 12,75 mld. | |
+27,29% | 12,06 mld. | |
-3,50% | 11,75 mld. |